Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Latham

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
Nature Communications|October 14, 2018
Variants in exons 5 and 6 of ACTB cause syndromic thrombocytopeniaSharissa L Latham, Nadja Ehmke, Patrick Y A Reinke, et al.
Nature Communications|November 20, 2018
Author Correction: Variants in exons 5 and 6 of ACTB cause syndromic thrombocytopeniaSharissa L Latham, Nadja Ehmke, Patrick Y A Reinke, et al.
Science Advances|March 3, 2023
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastomaJordan F Hastings, Sharissa L Latham, Alvin Kamili, et al.
Science Advances|May 1, 2023
Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouseJames R W Conway, Sean C Warren, Young-Kyung Lee, et al.
Cell Reports|September 15, 2021
Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imagingAlessia Floerchinger, Kendelle J Murphy, Sharissa L Latham, et al.
Communications Biology|October 18, 2023
Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infectionsPatrick Y A Reinke, Edmarcia Elisa de Souza, Sebastian Günther, et al.
Nature Cancer|August 28, 2023
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancerJessica L Chitty, Michelle Yam, Lara Perryman, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2024
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid MetabolismElysse C Filipe, Sipiththa Velayuthar, Ashleigh Philp, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
Nature Communications|October 14, 2018
Variants in exons 5 and 6 of ACTB cause syndromic thrombocytopeniaSharissa L Latham, Nadja Ehmke, Patrick Y A Reinke, et al.
Nature Communications|November 20, 2018
Author Correction: Variants in exons 5 and 6 of ACTB cause syndromic thrombocytopeniaSharissa L Latham, Nadja Ehmke, Patrick Y A Reinke, et al.
Science Advances|March 3, 2023
Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastomaJordan F Hastings, Sharissa L Latham, Alvin Kamili, et al.
Science Advances|May 1, 2023
Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouseJames R W Conway, Sean C Warren, Young-Kyung Lee, et al.
Cell Reports|September 15, 2021
Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imagingAlessia Floerchinger, Kendelle J Murphy, Sharissa L Latham, et al.
Communications Biology|October 18, 2023
Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infectionsPatrick Y A Reinke, Edmarcia Elisa de Souza, Sebastian Günther, et al.
Nature Cancer|August 28, 2023
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancerJessica L Chitty, Michelle Yam, Lara Perryman, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2024
Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid MetabolismElysse C Filipe, Sipiththa Velayuthar, Ashleigh Philp, et al.
Pageof 10